Abstract
Purpose: This large two-part, three-arm phase I study examined the safety and tolerability of CC-486 (an oral formulation of azacitidine, a hypomethylating agent) alone or in combination with the cytotoxic agents, carboplatin or nab-paclitaxel, in patients with advanced unresectable solid tumors.Patients and Methods: Part 1 (n = 57) was a dose escalation of CC-486 alone (arm C) or with carboplatin (arm A) or nab-paclitaxel (arm B). The primary endpoint was safety, MTD, and recommended part 2 dose (RP2D) of CC-486. In part 2 (n = 112), the primary endpoint was the safety and tolerability of CC-486 administered at the RP2D for each treatment arm, in tumor-specific expansion cohorts. Secondary endpoints included pharmacokinetics, pharmacodynamics, and antitumor activity of CC-486.Results: At pharmacologically active doses CC-486 in combination with carboplatin or nab-paclitaxel had a tolerable safety profile and no drug-drug interactions. The CC-486 RP2D was determined as 300 mg (every day, days 1-14/21) in combination with carboplatin (arm A) or as monotherapy (arm C); and 200 mg in the same dosing regimen in combination with nab-paclitaxel (arm B). Albeit limited by the small sample size, CC-486 monotherapy resulted in partial r...Continue Reading
References
Jul 12, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Y K OngE H Tan
Aug 12, 2003·Oncogene·Bruce F Israel, Shannon C Kenney
Mar 29, 2005·The Oncologist·Edvardas KaminskasRichard Pazdur
Feb 27, 2007·Cell·Peter A Jones, Stephen B Baylin
Oct 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kim AppletonRobert Brown
Jun 10, 2008·Urology·Donghao ShangOsamu Ogawa
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Dec 27, 2008·American Journal of Obstetrics and Gynecology·Yanfang LiSiqing Fu
Apr 8, 2010·Cell·Sreenath V SharmaJeff Settleman
Nov 26, 2010·Gut·Sascha VenturelliMichael Bitzer
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
May 18, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guillermo Garcia-ManeroBarry Skikne
Oct 1, 2009·Epigenomics·Marina BibikovaKevin L Gunderson
Dec 1, 2011·Epigenomics·Sarah DedeurwaerderFrançois Fuks
May 16, 2012·Cancer Discovery·Rosalyn A JuergensCharles M Rudin
Oct 25, 2013·Current Oncology·Tao XuH Yang
Oct 29, 2013·Oncotarget·John WrangleStephen B Baylin
Mar 4, 2014·Oncotarget·Huili LiNita Ahuja
Nov 2, 2014·Oncotarget·Wenfeng FangLi Zhang
Aug 22, 2015·PloS One·Eric LailleKyle J MacBeth
Oct 8, 2015·Leukemia·G Garcia-ManeroB Skikne
Jan 20, 2016·Future Oncology·Gail J RobozHagop Kantarjian
May 6, 2016·BMC Hematology·Guillermo Garcia-ManeroValeria Santini
Citations
Jan 8, 2019·Journal of Dental Research·M V Bais
Apr 24, 2019·Cancer·Stéphanie L GaillardNilofer Azad
Aug 14, 2020·Cells·Sandra P NunesJesús M Paramio
Aug 6, 2020·Journal for Immunotherapy of Cancer·Kirsty TaylorDaniel D De Carvalho
Apr 13, 2021·Journal of Biomedical Science·Kunal Nepali, Jing-Ping Liou
Aug 29, 2021·Clinical Epigenetics·Chunhong HuFang Wu